Literature DB >> 12905663

[A forty-year study on hypertension].

Li-sheng Liu1, Meng-qin Chen, Gui-yun Zeng, Bei-fan Zhou.   

Abstract

Since 1959 the investigations on prevalence of hypertension and studies on the prevention and treatment of this disease have been carried out. The vascular mechanism of hypertension and the depressor effect of Chinese traditional herbs were also studied in Chinese Academy of Medical Sciences. The results revealed that: (1) The prevalence of hypertension in Chinese adults increased from 7.73% in 1979 to 11.26% in 1991, both much higher than that in 1959 (5.11%). The rate of awareness, treatment and control was only 26.3%, 12.1%, and 2.8% respectively. The risk factors of hypertension included overweight and alcohol drinking. High sodium, low potassium, low calcium, and low animal protein diet were also very important risk for elevation of blood pressure. Hypertension was the most important causal risk factor of coronary heart disease and stroke. (2) Hypertension diagnosis and staging criteria were established in 1959. Secondary hypertension was found to constitute 1.1% among community hypertensive patients. The new concept of aortitis was formed and found to be the most common cause of renal vascular hypertension. Patient education together with low dose compounds of antihypertensive drugs was implicated widely. Randomized clinical trials Syst-China, Post-stroke Antihypertensive Treatment Study, Chinese Acute Stroke Trial, and Chinese Cardiac Study 1 demonstrated benefits of treatment for hypertensive, stroke or acute myocardial infarction affordable by Chinese population at large. (3) A series of functional changes and abnormalities with evident hereditary characteristics were found in the processes of cellular Ca2+ transportation, utilization, metabolism and their modulation of the vascular smooth muscle in SHR, and SHRsp, which seem to be the principal cause of the increase in peripheral vascular resistance in hypertension. (4) Alkaloid of Rauwolfia verticilata and Ligustrazine had marked depressor effect. Flavones of Radix Pueraricae could reduce the cardiac and cerebral ischemic damage and symptoms in hypertensive patients.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12905663

Source DB:  PubMed          Journal:  Zhongguo Yi Xue Ke Xue Yuan Xue Bao        ISSN: 1000-503X


  6 in total

1.  Diabetes and hypertension have become leading causes of CKD in Chinese elderly patients: a comparison between 1990-1991 and 2009-2010.

Authors:  Yali Cao; Wenge Li; Guannan Yang; Yutian Liu; Xin Li
Journal:  Int Urol Nephrol       Date:  2012-05-31       Impact factor: 2.370

2.  Clinical characteristics and outcomes of rural patients with ESRD in Guangxi, China: one dialysis center experience.

Authors:  Wenxin Zhang; Zhifeng Gong; Xiaomei Peng; Sheng Tang; Ming Bi; Wentan Huang
Journal:  Int Urol Nephrol       Date:  2009-07-14       Impact factor: 2.370

Review 3.  Chronic intermittent hypoxia and hypertension: a review of systemic inflammation and Chinese medicine.

Authors:  Chun-Xiao Wu; Yue Liu; Jing-Chun Zhang
Journal:  Chin J Integr Med       Date:  2013-05-15       Impact factor: 1.978

4.  Effect of tetramethylpyrazine on exocrine pancreatic and bile secretion.

Authors:  Wen-Chao Zhao; Jin-Xia Zhu; Ning Tang; Yu-Lin Gou; Dewi Kenneth Rowlands; Yiu-Wa Chung; Ying Xing; Hsiao-Chang Chan
Journal:  World J Gastroenterol       Date:  2003-11       Impact factor: 5.742

5.  Trends in the treatment of hypertension from the perspective of traditional chinese medicine.

Authors:  Xingjiang Xiong; Xiaochen Yang; Wei Liu; Fuyong Chu; Pengqian Wang; Jie Wang
Journal:  Evid Based Complement Alternat Med       Date:  2013-06-26       Impact factor: 2.629

Review 6.  A research agenda for aging in China in the 21st century.

Authors:  Evandro Fei Fang; Morten Scheibye-Knudsen; Heiko J Jahn; Juan Li; Li Ling; Hongwei Guo; Xinqiang Zhu; Victor Preedy; Huiming Lu; Vilhelm A Bohr; Wai Yee Chan; Yuanli Liu; Tzi Bun Ng
Journal:  Ageing Res Rev       Date:  2015-08-22       Impact factor: 10.895

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.